Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Mesalizine-Induced Acute Pancreatitis and Interstitial Pneumonitis in a Patient with Ulcerative Colitis

  • Chung, Min Jae (Department of Pediatrics, Chosun University School of Medicine) ;
  • Lee, Jae Hee (Department of Pediatrics, Chosun University School of Medicine) ;
  • Moon, Kyung Rye (Department of Pediatrics, Chosun University School of Medicine)
  • Received : 2015.04.29
  • Accepted : 2015.06.19
  • Published : 2015.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Ulcerative colitis (UC) is a chronic idiopathic inflammatory bowel disease. Mesalizine for the first-line therapy of UC has adverse effects include pancreatitis, pneumonia and pericarditis. UC complicated by two coexisting conditions, however, is very rare. Moreover, drug-related pulmonary toxicity is particularly rare. An 11-year-old male patient was hospitalized for recurring upper abdominal pain after meals with vomiting, hematochezia and exertional dyspnea developing at 2 weeks of mesalizine therapy for UC. The serum level of lipase was elevated. Chest X-ray and thorax computed tomography showed interstitial pneumonitis. Mesalizine was discontinued and steroid therapy was initiated. Five days after admission, symptoms were resolved and mesalizine was resumed after a drop in amylase and lipase level. Symptoms returned the following day, however, accompanied by increased the serum levels of amylase and lipase. Mesalizine was discontinued again and recurring symptoms rapidly improved.

Keywords

References

  1. Yang SK. Current status and clinical characteristics of inflammatory bowel disease in Korea. Korean J Gastroenterol 2002;40:1-14.
  2. Seo JK, Yeon KM, Chi JG. Inflammatory bowel disease in children--clinical, endoscopic, radiologic and histopathologic investigation. J Korean Med Sci 1992;7:221-35. https://doi.org/10.3346/jkms.1992.7.3.221
  3. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34. https://doi.org/10.1038/nature06005
  4. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002;51:536-9. https://doi.org/10.1136/gut.51.4.536
  5. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8. https://doi.org/10.1136/gut.37.5.674
  6. Williams T, Eidus L, Thomas P. Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy. Chest 1982;81:766-8. https://doi.org/10.1378/chest.81.6.766
  7. Fardy JM, Lloyd DA, Reynolds RP. Adverse effects with oral 5-aminosalicyclic acid. J Clin Gastroenterol 1988;10:635-7. https://doi.org/10.1097/00004836-198812000-00012
  8. Toubanakis C, Batziou E, Sipsas N, Galanopoulos G, Tzivras M, Archimandritis A. Acute pancreatitis after long-term therapy with mesalazine, and hyperamylasaemia associated with azathioprine in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:933-4. https://doi.org/10.1097/00042737-200308000-00019
  9. Woltsche M, Woltsche-Kahr I, Roeger GM, Aberer W, Popper H. Sulfasalazine-induced extrinsic allergic alveolitis in a patient with psoriatic arthritis. Eur J Med Res 2001;6:495-7.
  10. Chikano S, Sawada K, Ohnishi K, Fukunaga K, Tanaka J, Shimoyama T. Interstitial pneumonia accompanying ulcerative colitis. Intern Med 2001;40:883-6. https://doi.org/10.2169/internalmedicine.40.883
  11. Herrlinger KR, Stange EF. The pancreas and inflammatory bowel diseases. Int J Pancreatol 2000;27:171-9. https://doi.org/10.1385/IJGC:27:3:171
  12. Fiorentini MT, Fracchia M, Galatola G, Barlotta A, de la Pierre M. Acute pancreatitis during oral 5-aminosalicylic acid therapy. Dig Dis Sci 1990;35:1180-2. https://doi.org/10.1007/BF01537594
  13. Lankisch PG, Droge M, Gottesleben F. Drug induced acute pancreatitis: incidence and severity. Gut 1995;37:565-7. https://doi.org/10.1136/gut.37.4.565
  14. Balani AR, Grendell JH. Drug-induced pancreatitis : incidence, management and prevention. Drug Saf 2008;31:823-37. https://doi.org/10.2165/00002018-200831100-00002
  15. Castiglione F, Del Vecchio Blanco G, Rispo A, Mazzacca G. Prevention of pancreatitis by weekly amylase assay in patients with Crohn's disease treated with azathioprine. Am J Gastroenterol 2000;95:2394-5. https://doi.org/10.1111/j.1572-0241.2000.02347.x
  16. Foster RA, Zander DS, Mergo PJ, Valentine JF. Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations. Inflamm Bowel Dis 2003;9:308-15. https://doi.org/10.1097/00054725-200309000-00004
  17. Camus P, Piard F, Ashcroft T, Gal AA, Colby TV. The lung in inflammatory bowel disease. Medicine (Baltimore) 1993;72:151-83. https://doi.org/10.1097/00005792-199372030-00003
  18. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006;12:4819-31. https://doi.org/10.3748/wjg.v12.i30.4819
  19. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. https://doi.org/10.1056/NEJMoa050516

Cited by

  1. Efficacy and safety of stellate ganglion block in chronic ulcerative colitis vol.23, pp.3, 2015, https://doi.org/10.3748/wjg.v23.i3.533
  2. Acute pancreatitis induced by etoposide–lobaplatin combination chemotherapy used for the treatment of lung cancer : A case report and literature review vol.96, pp.29, 2017, https://doi.org/10.1097/md.0000000000007601
  3. Drug Induced Acute Pancreatitis vol.22, pp.4, 2017, https://doi.org/10.15279/kpba.2017.22.4.153